China Shingles Vaccine (Shingrix) Market Report 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Shingles Vaccine Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The trade name of Shingles Vaccine is SHINGRIX, which was developed by GlaxoSmithKline. Its product was firstly approved in China in 2020.

Recombinant zoster vaccine is suitable for adults aged 50 years and over to protect against shingles (herpes zoster). The recombinant zoster vaccine has been listed in the Chinese market. By 2020, GlaxoSmithKline Biologicals is the only manufacturer in the Chinese Shingles Vaccine market.

According to the market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY2 million, and its annual sales volume reached 1,745 doses. Therefore, the development prospects are quite good.

According to the analysis, from 2021 to 2025, as the Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase.

Topics Covered:

• The impact of COVID-19 on China’s Shingles Vaccine market
• Sales value of China’s Shingles Vaccine 2016-2020
• Competitive landscape of China’s Shingles Vaccine market
• Prices of Shingles Vaccine in China
• Prices of Shingles Vaccine in China by regions and manufacturers
• Analysis on factors affecting the development of China’s Shingles Vaccine market
• Prospect of China’s Shingles Vaccine market from 2021 to 2025

Key Topics Covered:

1 Relevant Concept of Shingles Vaccine

1.1 Indications for Shingles Vaccine

1.2 Development of Shingles Vaccine in China

1.3 Governmental Approval of Shingles Vaccine in China

1.4 The Impact of COVID-19 on Shingles Vaccine sales in China

2 Sales of Shingles Vaccine in China in 2020

2.1 Sales Value of Shingles Vaccine

2.1.1 Overall Sales Value

2.1.2 Sales Value by Regions

2.2 Sales Volume of Shingles Vaccine

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 Sales of Shingles Vaccine by Dosage Form in China in 2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Shingles Vaccine Manufacturers in China in 2020

3.1 Analysis of Market Share of Major Shingles Vaccine Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Glaxo SmithKline Biologicals

3.2.1 Enterprise Profile

3.2.2 Sales of SHINGRIX (Glaxo SmithKline Biologicals’ Shingles Vaccine) in China

4 Prices of Shingles Vaccine for Different Manufacturers in China, 2020-2021

4.1 Glaxo SmithKline Biologicals (SHINGRIX)

5 Prospect of Chinese Shingles Vaccine drug Market, 2021-2025

5.1 Influential Factors of Chinese Shingles Vaccine Market Development

5.1.1 The Impact of COVID-19 on Chinese Shingles Vaccine Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

Companies Mentioned

• GlaxoSmithKline Biologicals
• Merck

For more information about this report visit https://www.researchandmarkets.com/r/jtogzj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900